TipRanks
Go Ultimate55% OFF

Corcept Therapeutics (0I3Q) Share Forecast & Price Target

See the Price Targets and Ratings of:All AnalystsTop AnalystsPremium

0I3Q Analyst Ratings

Strong Buy
4Ratings
4Buy0Hold0Sell
Based on 4 analysts giving stock ratings to Corcept Therapeutics in the past 3 months

0I3Q Stock 12 Month Forecast

$163.75▲(103.49% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Corcept Therapeutics in the last 3 months. The average price target is $163.75 with a high forecast of $165.00 and a low forecast of $161.00. The average price target represents a 103.49% change from the last price of $80.47.
Highest Price Target$165.00Average Price Target$163.75Lowest Price Target$161.00

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for GB:0I3Q
Analyst ProfileExpert FirmPrice TargetPositionUpside / DownsideActionDateFollowArticle
Canaccord Genuity$161buy100.07%UpsideReiterated10/27/26
Piper Sandler$165buy105.05%UpsideReiterated10/27/26
H.C. Wainwright$165buy105.05%UpsideReiterated10/01/26
Truist Financial$50→$164buy103.80%UpsideInitiated08/18/26
Wolfe Research$50sell-37.87%DownsideReiterated07/29/26
UBS$72buy-10.53%DownsideUpgraded05/13/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
MDWDMediwound
IMUXImmunic
RZLTRezolute
DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Corcept Therapeutics

3 Months
Edward Nash
Edward NashCanaccord Genuity
Success Rate23/35 ratings generated profit
66%
Average Return
+13.91%

Copying Edward Nash's trades and holding each position for 3 Months would result in 65.71% of your transactions generating a profit, with an average return of +13.91% per trade.

1 Year
David Amsellem
David AmsellemPiper Sandler
Success Rate22/29 ratings generated profit
76%
Average Return
+51.67%

Copying David Amsellem's trades and holding each position for 1 Year would result in 75.86% of your transactions generating a profit, with an average return of +51.67% per trade.

2 Years
David Amsellem
David AmsellemPiper Sandler
Success Rate26/29 ratings generated profit
90%
Average Return
+83.66%

Copying David Amsellem's trades and holding each position for 2 Years would result in 89.66% of your transactions generating a profit, with an average return of +83.66% per trade.

0I3Q Analyst Recommendation Trends

010203040Oct 25Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26
Monthly rating counts for 0I3Q
RatingMay 26Jun 26Jul 26Aug 26Sep 26
Strong Buy53002
Buy5101098
Hold00000
Sell02220
Strong Sell00000
total1015121110

In the current month, 0I3Q has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0I3Q average Analyst price target in the past 3 months is 163.75.

0I3Q Financial Forecast

$-2$-1$0$1$2Q4 2025Q2 2026Q3 2026
High$1.03
Consensus$0.79
Low$0.61

0I3Q Earnings Forecast

Next quarter’s earnings estimate for 0I3Q is $0.79 with a range of $0.61 to $1.03. The previous quarter’s EPS was $0.36. 0I3Q beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0I3Q has Performed in-line its overall industry.

$164.9M$211.2M$257.5M$303.7M$350MQ4 2025Q2 2026Q3 2026
High$350M
Consensus$324M
Low$274M

0I3Q Sales Forecast

Next quarter’s sales forecast for 0I3Q is $323.90M with a range of $274.00M to $350.00M. The previous quarter’s sales results were $256.15M. 0I3Q beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0I3Q has Performed in-line its overall industry.

0I3Q Stock Forecast FAQ

What is GB:0I3Q’s average 12-month price target, according to analysts?
Based on analyst ratings, Corcept Therapeutics’s 12-month average price target is $163.75.
What is GB:0I3Q’s upside potential, based on the analysts’ average price target?
Corcept Therapeutics has 103.49% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Corcept Therapeutics a Buy, Sell or Hold?
Corcept Therapeutics has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Corcept Therapeutics’s share price target?
The average share price target for Corcept Therapeutics is $163.75. This is based on 4 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $165.00, and the lowest forecast is $161.00. The average share price target represents a 103.49% increase from the current price of $80.47.
What do analysts say about Corcept Therapeutics?
Corcept Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Street analysts.
How can I buy shares of Corcept Therapeutics?
To buy shares of GB:0I3Q, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.